{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,13]],"date-time":"2026-06-13T09:18:03Z","timestamp":1781342283590,"version":"3.54.1"},"reference-count":47,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2022,4,1]],"date-time":"2022-04-01T00:00:00Z","timestamp":1648771200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,4,1]],"date-time":"2022-04-01T00:00:00Z","timestamp":1648771200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,5,2]],"date-time":"2023-05-02T00:00:00Z","timestamp":1682985600000},"content-version":"am","delay-in-days":396,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.fr","em-consulte.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["La Revue de M\u00e9decine Interne"],"published-print":{"date-parts":[[2022,4]]},"DOI":"10.1016\/j.revmed.2022.01.006","type":"journal-article","created":{"date-parts":[[2022,2,24]],"date-time":"2022-02-24T23:19:07Z","timestamp":1645744747000},"page":"242-251","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"title":["L\u2019orbitopathie basedowienne: diagnostic, \u00e9pid\u00e9miologie et principes de traitement"],"prefix":"10.1016","volume":"43","author":[{"given":"A. Yan","family":"Lun","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Le Bras","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"E.","family":"Scharbarg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"P.","family":"Morcel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.","family":"Hadjadj","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"P.","family":"Lebranchu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"D.","family":"Drui","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"4","key":"10.1016\/j.revmed.2022.01.006_bib0005","doi-asserted-by":"crossref","first-page":"374","DOI":"10.1590\/2359-3997000000252","article-title":"Related quality of life questionnaire specific to dysthyroid ophthalmopathy evaluated in a population of patients with Graves\u2019 disease","volume":"61","author":"Delfino","year":"2017","journal-title":"Arch Endocrinol Metab"},{"issue":"6","key":"10.1016\/j.revmed.2022.01.006_bib0010","doi-asserted-by":"crossref","first-page":"599","DOI":"10.1016\/j.ando.2018.09.002","article-title":"V\u00e9layoudom-C\u00e9phise F-L. Graves\u2019 disease: Introduction, epidemiology, endogenous and environmental pathogenic factors","volume":"79","author":"W\u00e9meau","year":"2018","journal-title":"Ann Endocrinol"},{"issue":"3","key":"10.1016\/j.revmed.2022.01.006_bib0015","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1016\/j.survophthal.2009.06.009","article-title":"Immunopathogenesis of thyroid eye disease: emerging paradigms","volume":"55","author":"Naik","year":"2010","journal-title":"Surv Ophthalmol"},{"key":"10.1016\/j.revmed.2022.01.006_bib0020","first-page":"477","article-title":"The epidemiologic characteristics and clinical course of ophthalmopathy associated with autoimmune thyroid disease in Olmsted County, Minnesota","volume":"92","author":"Bartley","year":"1994","journal-title":"Trans Am Ophthalmol Soc"},{"issue":"4","key":"10.1016\/j.revmed.2022.01.006_bib0025","doi-asserted-by":"crossref","first-page":"1443","DOI":"10.1210\/jc.2012-3873","article-title":"Prevalence and natural history of graves\u2019 orbitopathy in a large series of patients with newly diagnosed Graves\u2019 hyperthyroidism seen at a single center","volume":"98","author":"Tanda","year":"2013","journal-title":"J Clin Endocrinol Metab"},{"issue":"10","key":"10.1016\/j.revmed.2022.01.006_bib0030","doi-asserted-by":"crossref","first-page":"874","DOI":"10.1016\/j.jfo.2013.07.004","article-title":"Diagnosis and treatment of dysthyroid orbitopathy: a multidisciplinary disease","volume":"36","author":"Leray","year":"2013","journal-title":"J Fr Ophtalmol"},{"issue":"1","key":"10.1016\/j.revmed.2022.01.006_bib0035","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1186\/s13023-017-0625-1","article-title":"Graves\u2019 orbitopathy as a rare disease in Europe: a European group on Graves\u2019 orbitopathy (EUGOGO) position statement","volume":"12","author":"Perros","year":"2017","journal-title":"Orphanet J Rare Dis"},{"issue":"11","key":"10.1016\/j.revmed.2022.01.006_bib0040","doi-asserted-by":"crossref","first-page":"1531","DOI":"10.1136\/bjophthalmol-2015-306733","article-title":"PREGO (presentation of Graves\u2019 orbitopathy) study: changes in referral patterns to European Group On Graves\u2019 Orbitopathy (EUGOGO) centres over the period from 2000\u00a0to 2012","volume":"99","author":"Perros","year":"2015","journal-title":"Br J Ophthalmol"},{"issue":"4","key":"10.1016\/j.revmed.2022.01.006_bib0045","doi-asserted-by":"crossref","first-page":"1443","DOI":"10.1210\/jc.2012-3873","article-title":"Prevalence and natural history of graves\u2019 orbitopathy in a large series of patients with newly diagnosed Graves\u2019 hyperthyroidism seen at a single center","volume":"98","author":"Tanda","year":"2013","journal-title":"J Clin Endocrinol Metab"},{"issue":"7","key":"10.1016\/j.revmed.2022.01.006_bib0050","doi-asserted-by":"crossref","first-page":"777","DOI":"10.1089\/thy.2010.1634","article-title":"Risk factors for development or deterioration of Graves\u2019 ophthalmopathy","volume":"20","author":"Stan","year":"2010","journal-title":"Thyroid"},{"issue":"3","key":"10.1016\/j.revmed.2022.01.006_bib0055","doi-asserted-by":"crossref","first-page":"356","DOI":"10.1001\/archophthalmol.2011.29","article-title":"Rundle and his curve","volume":"129","author":"Bartley","year":"2011","journal-title":"Arch Ophthalmol"},{"issue":"1","key":"10.1016\/j.revmed.2022.01.006_bib0060","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1136\/bjo.88.1.75","article-title":"Assessing quality of life in Australian patients with Graves\u2019 ophthalmopathy","volume":"88","author":"Park","year":"2004","journal-title":"Br J Ophthalmol"},{"issue":"0","key":"10.1016\/j.revmed.2022.01.006_bib0065","first-page":"56","article-title":"Work of the Council of Deputies and of the Coordination Center of Comecom member countries on the subject of \u00ab The creation of biomedical devices and apparatus for research and clinical medicine \u00bb","volume":"3","author":"Utiamyshev","year":"1974","journal-title":"Med Tekh"},{"issue":"3","key":"10.1016\/j.revmed.2022.01.006_bib0070","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1046\/j.1365-2265.2001.01349.x","article-title":"Controversies in the clinical evaluation of active thyroid-associated orbitopathy: use of a detailed protocol with comparative photographs for objective assessment","volume":"55","author":"Dickinson","year":"2001","journal-title":"Clin Endocrinol (Oxf)"},{"issue":"1","key":"10.1016\/j.revmed.2022.01.006_bib0075","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1076\/soph.17.1.18.10289","article-title":"Dysthyroid optic neuropathy (DON)","volume":"17","author":"Ebner","year":"2002","journal-title":"Semin Ophthalmol"},{"issue":"1","key":"10.1016\/j.revmed.2022.01.006_bib0080","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1007\/s40123-019-00226-9","article-title":"Current understanding of the progression and management of thyroid associated orbitopathy: a systematic review","volume":"9","author":"Hodgson","year":"2020","journal-title":"Ophthalmol Ther"},{"issue":"9","key":"10.1016\/j.revmed.2022.01.006_bib0085","doi-asserted-by":"crossref","first-page":"2013","DOI":"10.1007\/s00417-020-04651-6","article-title":"Efficacy of rituximab in patients with Graves\u2019 orbitopathy: a retrospective multicenter nationwide study","volume":"258","author":"Deltour","year":"2020","journal-title":"Graefes Arch Clin Exp Ophthalmol"},{"issue":"3","key":"10.1016\/j.revmed.2022.01.006_bib0090","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1016\/j.beem.2011.09.004","article-title":"Prevention of Graves\u2019 ophthalmopathy","volume":"26","author":"Bartalena","year":"2012","journal-title":"Best Pract Res Clin Endocrinol Metab"},{"issue":"10","key":"10.1016\/j.revmed.2022.01.006_bib0095","doi-asserted-by":"crossref","first-page":"746","DOI":"10.20452\/pamw.3505","article-title":"Efficacy and safety of radioiodine therapy for mild Graves ophthalmopathy depending on cigarette consumption: a 6-month follow-up","volume":"126","author":"Czarnywojtek","year":"2016","journal-title":"Pol Arch Med Wewn"},{"issue":"20","key":"10.1016\/j.revmed.2022.01.006_bib0100","doi-asserted-by":"crossref","first-page":"1920","DOI":"10.1056\/NEJMoa1012985","article-title":"Selenium and the course of mild Graves\u2019 orbitopathy","volume":"364","author":"Marcocci","year":"2011","journal-title":"N Engl J Med"},{"issue":"10","key":"10.1016\/j.revmed.2022.01.006_bib0105","doi-asserted-by":"crossref","first-page":"754","DOI":"10.1016\/j.numecd.2010.10.001","article-title":"Selenium status and cardiometabolic health: State of the evidence","volume":"20","author":"Stranges","year":"2010","journal-title":"Nutr Metab Cardiovasc Dis"},{"issue":"6","key":"10.1016\/j.revmed.2022.01.006_bib0110","doi-asserted-by":"crossref","first-page":"1999","DOI":"10.1210\/jc.2013-3919","article-title":"A prospective, randomized trial of intravenous glucocorticoids therapy with different protocols for patients with graves\u2019 ophthalmopathy","volume":"99","author":"Zhu","year":"2014","journal-title":"J Clin Endocrinol Metab"},{"issue":"12","key":"10.1016\/j.revmed.2022.01.006_bib0115","doi-asserted-by":"crossref","first-page":"4454","DOI":"10.1210\/jc.2012-2389","article-title":"Efficacy and safety of three different cumulative doses of intravenous methylprednisolone for moderate to severe and active Graves\u2019 orbitopathy","volume":"97","author":"Bartalena","year":"2012","journal-title":"J Clin Endocrinol Metab"},{"issue":"5","key":"10.1016\/j.revmed.2022.01.006_bib0120","doi-asserted-by":"crossref","first-page":"547","DOI":"10.1007\/s40618-017-0608-z","article-title":"Does early response to intravenous glucocorticoids predict the final outcome in patients with moderate-to-severe and active Graves\u2019 orbitopathy?","volume":"40","author":"Bartalena","year":"2017","journal-title":"J Endocrinol Invest"},{"issue":"9","key":"10.1016\/j.revmed.2022.01.006_bib0125","doi-asserted-by":"crossref","first-page":"5234","DOI":"10.1210\/jc.2005-0148","article-title":"Randomized, single blind trial of intravenous versus oral steroid monotherapy in Graves\u2019 orbitopathy","volume":"90","author":"Kahaly","year":"2005","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.revmed.2022.01.006_bib0130","doi-asserted-by":"crossref","first-page":"4845894","DOI":"10.1155\/2018\/4845894","article-title":"Corticosteroids for Graves\u2019 Ophthalmopathy: Systematic Review and Meta-Analysis","volume":"2018","author":"Tu","year":"2018","journal-title":"BioMed Res Int"},{"issue":"5","key":"10.1016\/j.revmed.2022.01.006_bib0135","first-page":"362","article-title":"Efficacy and safety of pulsed intravenous methylprednisolone in early active thyroid eye disease","volume":"38","author":"Young","year":"2019","journal-title":"Orbit Amst Neth"},{"issue":"1","key":"10.1016\/j.revmed.2022.01.006_bib0140","doi-asserted-by":"crossref","first-page":"101366","DOI":"10.1016\/j.beem.2019.101366","article-title":"Novel therapies for thyroid autoimmune diseases: An update","volume":"34","author":"Ferrari","year":"2020","journal-title":"Best Pract Res Clin Endocrinol Metab"},{"issue":"2","key":"10.1016\/j.revmed.2022.01.006_bib0145","doi-asserted-by":"crossref","first-page":"422","DOI":"10.1210\/jc.2014-3014","article-title":"Efficacy of B-cell targeted therapy with rituximab in patients with active moderate to severe Graves\u2019 orbitopathy: a randomized controlled study","volume":"100","author":"Salvi","year":"2015","journal-title":"J Clin Endocrinol Metab"},{"issue":"2","key":"10.1016\/j.revmed.2022.01.006_bib0150","doi-asserted-by":"crossref","first-page":"432","DOI":"10.1210\/jc.2014-2572","article-title":"Randomized controlled trial of rituximab in patients with Graves\u2019 orbitopathy","volume":"100","author":"Stan","year":"2015","journal-title":"J Clin Endocrinol Metab"},{"issue":"2","key":"10.1016\/j.revmed.2022.01.006_bib0155","doi-asserted-by":"crossref","first-page":"R101","DOI":"10.1530\/EJE-16-0552","article-title":"Management of endocrine disease: Rituximab therapy for Graves\u2019 orbitopathy - lessons from randomized control trials","volume":"176","author":"Stan","year":"2017","journal-title":"Eur J Endocrinol"},{"issue":"5","key":"10.1016\/j.revmed.2022.01.006_bib0160","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1002\/phar.2111","article-title":"Safety of rituximab for the treatment of graves\u2019 orbitopathy: a meta-analysis of randomized controlled trials","volume":"38","author":"Shen","year":"2018","journal-title":"Pharmacotherapy"},{"issue":"1","key":"10.1016\/j.revmed.2022.01.006_bib0165","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1111\/cen.13970","article-title":"Early low-dose rituximab for active thyroid eye disease: An effective and well-tolerated treatment","volume":"91","author":"Insull","year":"2019","journal-title":"Clin Endocrinol (Oxf)"},{"issue":"5","key":"10.1016\/j.revmed.2022.01.006_bib0170","doi-asserted-by":"crossref","first-page":"1008","DOI":"10.1177\/1120672119845224","article-title":"Korobelnik J-F. The effects of Rituximab on Graves\u2019orbitopathy: A retrospective study of 14\u00a0patients","volume":"30","author":"Eid","year":"2020","journal-title":"Eur J Ophthalmol"},{"key":"10.1016\/j.revmed.2022.01.006_bib0175","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1016\/j.ajo.2018.07.038","article-title":"Efficacy of tocilizumab in patients with moderate-to-severe corticosteroid-resistant Graves orbitopathy: a randomized clinical trial","volume":"195","author":"Perez-Moreiras","year":"2018","journal-title":"Am J Ophthalmol"},{"issue":"2","key":"10.1016\/j.revmed.2022.01.006_bib0180","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1080\/09273948.2018.1545914","article-title":"Tocilizumab for the management of corticosteroid-resistant mild to severe Graves\u2019 ophthalmopathy, a report of three cases","volume":"28","author":"Maldiney","year":"2020","journal-title":"Ocul Immunol Inflamm"},{"issue":"18","key":"10.1016\/j.revmed.2022.01.006_bib0185","doi-asserted-by":"crossref","first-page":"1748","DOI":"10.1056\/NEJMoa1614949","article-title":"Teprotumumab for thyroid-associated ophthalmopathy","volume":"376","author":"Smith","year":"2017","journal-title":"N Engl J Med"},{"issue":"7","key":"10.1016\/j.revmed.2022.01.006_bib0190","doi-asserted-by":"crossref","first-page":"645","DOI":"10.1080\/13543784.2020.1772752","article-title":"Teprotumumab: a novel therapeutic monoclonal antibody for thyroid-associated ophthalmopathy","volume":"29","author":"Slentz","year":"2020","journal-title":"Expert Opin Investig Drugs"},{"issue":"20","key":"10.1016\/j.revmed.2022.01.006_bib0195","doi-asserted-by":"crossref","first-page":"1353","DOI":"10.1056\/NEJM198911163212002","article-title":"Prednisone and cyclosporine in the treatment of severe Graves\u2019 ophthalmopathy","volume":"321","author":"Prummel","year":"1989","journal-title":"N Engl J Med"},{"issue":"2","key":"10.1016\/j.revmed.2022.01.006_bib0200","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1111\/cen.13170","article-title":"Efficacy and safety of mycophenolate mofetil in patients with active moderate-to-severe Graves\u2019 orbitopathy","volume":"86","author":"Ye","year":"2017","journal-title":"Clin Endocrinol (Oxf)"},{"issue":"5","key":"10.1016\/j.revmed.2022.01.006_bib0205","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1097\/IOP.0000000000000211","article-title":"Adalimumab as steroid-sparing treatment of inflammatory-stage thyroid eye disease","volume":"30","author":"Ayabe","year":"2014","journal-title":"Ophthal Plast Reconstr Surg"},{"issue":"12","key":"10.1016\/j.revmed.2022.01.006_bib0210","first-page":"1286","article-title":"The effect of etanercept on Graves\u2019 ophthalmopathy: a pilot study","volume":"19","author":"Paridaens","year":"2005","journal-title":"Eye Lond Engl"},{"issue":"8877","key":"10.1016\/j.revmed.2022.01.006_bib0215","doi-asserted-by":"crossref","first-page":"949","DOI":"10.1016\/0140-6736(93)92001-A","article-title":"Randomized double-blind trial of prednisone versus radiotherapy in Graves\u2019 ophthalmopathy","volume":"342","author":"Prummel","year":"1993","journal-title":"Lancet Lond Engl"},{"issue":"8","key":"10.1016\/j.revmed.2022.01.006_bib0220","first-page":"3562","article-title":"Comparison of the effectiveness and tolerability of intravenous or oral glucocorticoids associated with orbital radiotherapy in the management of severe Graves\u2019 ophthalmopathy: results of a prospective, single-blind, randomized study","volume":"86","author":"Marcocci","year":"2001","journal-title":"J Clin Endocrinol Metab"},{"issue":"1","key":"10.1016\/j.revmed.2022.01.006_bib0225","first-page":"e84427","article-title":"Orbital radiotherapy plus concomitant steroids in moderate-to-severe Graves\u2019 ophthalmopathy: good results after long-term follow-up","volume":"17","author":"Nicosia","year":"2019","journal-title":"Int J Endocrinol Metab"},{"issue":"11","key":"10.1016\/j.revmed.2022.01.006_bib0230","doi-asserted-by":"crossref","first-page":"1737","DOI":"10.18240\/ijo.2019.11.12","article-title":"The effect of intravenous high-dose glucocorticoids and orbital decompression surgery on sight-threatening thyroid-associated ophthalmopathy","volume":"12","author":"Wen","year":"2019","journal-title":"Int J Ophthalmol"},{"issue":"6","key":"10.1016\/j.revmed.2022.01.006_bib0235","doi-asserted-by":"crossref","first-page":"1183","DOI":"10.1016\/S0161-6420(02)01041-2","article-title":"Treatment of upper eyelid retraction associated with thyroid eye disease with subconjunctival botulinum toxin injection","volume":"109","author":"Uddin","year":"2002","journal-title":"Ophthalmology"}],"container-title":["La Revue de M\u00e9decine Interne"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0248866322000273?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0248866322000273?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T16:44:46Z","timestamp":1759337086000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0248866322000273"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,4]]},"references-count":47,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2022,4]]}},"alternative-id":["S0248866322000273"],"URL":"https:\/\/doi.org\/10.1016\/j.revmed.2022.01.006","relation":{},"ISSN":["0248-8663"],"issn-type":[{"value":"0248-8663","type":"print"}],"subject":[],"published":{"date-parts":[[2022,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"L\u2019orbitopathie basedowienne: diagnostic, \u00e9pid\u00e9miologie et principes de traitement","name":"articletitle","label":"Article Title"},{"value":"La Revue de M\u00e9decine Interne","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.revmed.2022.01.006","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 Soci\u00e9t\u00e9 Nationale Fran\u00e7aise de M\u00e9decine Interne (SNFMI). Published by Elsevier Masson SAS. All rights reserved.","name":"copyright","label":"Copyright"}]}}